{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T05:11:32Z","timestamp":1649135492422},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurolog\u00eda"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.nrl.2011.02.005","type":"journal-article","created":{"date-parts":[[2012,2,24]],"date-time":"2012-02-24T02:00:21Z","timestamp":1330048821000},"page":"39-45","source":"Crossref","is-referenced-by-count":0,"title":["Anticuerpos monoclonales en patolog\u00eda inflamatoria del sistema nervioso perif\u00e9rico y m\u00fasculo"],"prefix":"10.1016","volume":"27","author":[{"given":"J.J.","family":"Poza Aldea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrl.2011.02.005_bib0005","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/ncpneuro0901","article-title":"B cells as therapeutic targets in autoimmune neurological disorders","volume":"4","author":"Dalakas","year":"2008","journal-title":"Nat Clin Pract Neurol."},{"key":"10.1016\/j.nrl.2011.02.005_bib0010","doi-asserted-by":"crossref","unstructured":"Lunn MP, Nobile-Orazio E. Immunotherapy for IgM antimyelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 2003;1:CD002827.","DOI":"10.1002\/14651858.CD002827"},{"key":"10.1016\/j.nrl.2011.02.005_bib0015","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/mus.20386","article-title":"Worsening after rituximab treatment in anti-MAG neuropathy","volume":"32","author":"Broglio","year":"2005","journal-title":"Muscle Nerve."},{"key":"10.1016\/j.nrl.2011.02.005_bib0020","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/mus.10359","article-title":"Rituximab in the treatment of anti-MAG associated polyneuropathy","volume":"27","author":"Renaud","year":"2003","journal-title":"Muscle Nerve."},{"key":"10.1016\/j.nrl.2011.02.005_bib0025","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ana.21577","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy","volume":"65","author":"Dalakas","year":"2009","journal-title":"Ann Neurol."},{"key":"10.1016\/j.nrl.2011.02.005_bib0030","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0035-3787(06)75077-9","article-title":"Une polyneuropathie avec atteinte des nerfs cr\u00e2niens associ\u00e9e \u00e0 une IgM monoclonale \u00e0 activit\u00e9 anti-MAG\/SGPG\/SGPLG\/sulfatides","volume":"162","author":"Drouet","year":"2006","journal-title":"Rev Neurol (Paris)."},{"key":"10.1016\/j.nrl.2011.02.005_bib0035","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1212\/01.wnl.0000335268.70325.33","article-title":"Long-term effect of rituximab in anti-mag polyneuropathy","volume":"71","author":"Benedetti","year":"2008","journal-title":"Neurology."},{"key":"10.1016\/j.nrl.2011.02.005_bib0040","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1212\/01.wnl.0000201193.00382.b3","article-title":"High-dose rituximab and anti-MAG-associated polyneuropathy","volume":"66","author":"Renaud","year":"2006","journal-title":"Neurology."},{"key":"10.1016\/j.nrl.2011.02.005_bib0045","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1212\/01.WNL.0000098996.02934.86","article-title":"Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab","volume":"61","author":"Rojas-Garc\u00eda","year":"2003","journal-title":"Neurology."},{"key":"10.1016\/j.nrl.2011.02.005_bib0050","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/mus.20664","article-title":"Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial","volume":"35","author":"Gorson","year":"2007","journal-title":"Muscle Nerve."},{"key":"10.1016\/j.nrl.2011.02.005_bib0055","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1212\/01.WNL.0000145706.04340.25","article-title":"Rituximab stabilizes multifocal neuropathy increasingly less responsive to IV Ig","volume":"63","author":"R\u00fcegg","year":"2004","journal-title":"Neurology."},{"key":"10.1016\/j.nrl.2011.02.005_bib0060","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/jnnp.74.4.485","article-title":"Treatment of IgM antibody associated polyneuropathies using rituximab","volume":"74","author":"Pestronk","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.nrl.2011.02.005_bib0065","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1080\/14786410500441664","article-title":"Rituximab therapy in monoclonal IgM-related neuropathies","volume":"47","author":"Kilidireas","year":"2006","journal-title":"Leuk. Lymphoma."},{"key":"10.1016\/j.nrl.2011.02.005_bib0070","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/mus.20664","article-title":"Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot study","volume":"35","author":"Gorson","year":"2007","journal-title":"Muscle Nerve."},{"key":"10.1016\/j.nrl.2011.02.005_bib0075","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/jnnp.2005.076869","article-title":"Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H)","volume":"77","author":"Hirst","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.nrl.2011.02.005_bib0080","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2002-10-3162","article-title":"Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon a with an anti-CD20","volume":"101","author":"Sansonno","year":"2003","journal-title":"Blood."},{"key":"10.1016\/j.nrl.2011.02.005_bib0085","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1182\/blood-2002-09-2856","article-title":"Efficacy and safety of rituximab in type II mixed cryoglobulinemia","volume":"101","author":"Zaja","year":"2003","journal-title":"Blood."},{"key":"10.1016\/j.nrl.2011.02.005_bib0090","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1182\/blood-2005-03-0910","article-title":"Bevacizumab therapy for POEMS syndrome","volume":"106","author":"Badros","year":"2005","journal-title":"Blood."},{"key":"10.1016\/j.nrl.2011.02.005_bib0095","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1182\/blood-2005-12-5045","article-title":"Bevacizumab therapy for POEMS syndrome","volume":"107","author":"Straume","year":"2006","journal-title":"Blood."},{"key":"10.1016\/j.nrl.2011.02.005_bib0100","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2169\/internalmedicine.46.6246","article-title":"Failure of treatment with anti-VEGF monoclonal antibody for long-standing POEMS syndrome","volume":"46","author":"Kanai","year":"2007","journal-title":"Intern Med."},{"key":"10.1016\/j.nrl.2011.02.005_bib0105","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.3324\/haematol.11315","article-title":"Treatment of POEMS syndrome with bevacizumab","volume":"92","author":"Samaras","year":"2007","journal-title":"Haematologica."},{"key":"10.1016\/j.nrl.2011.02.005_bib0110","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/annonc\/mdm602","article-title":"Bevacizumab therapy before autologous stem-cell transplantation for POEMS syndrome","volume":"19","author":"Dietrich","year":"2008","journal-title":"Ann Oncol."},{"key":"10.1016\/j.nrl.2011.02.005_bib0115","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1196\/annals.1405.012","article-title":"Response to therapy in myasthenia gravis with anti-MuSK antibodies","volume":"1132","author":"Evoli","year":"2008","journal-title":"Ann N Y Acad Sci."},{"key":"10.1016\/j.nrl.2011.02.005_bib0120","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jneuroim.2008.04.039","article-title":"Sustained response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients","volume":"201\u2013202","author":"Illa","year":"2008","journal-title":"J Neuroimmunol."},{"key":"10.1016\/j.nrl.2011.02.005_bib0125","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1468-1331.2008.02399.x","article-title":"Successful treatment of refractory generalized myasthenia gravis with rituximab","volume":"16","author":"Lebrun","year":"2009","journal-title":"Eur J Neurol."},{"key":"10.1016\/j.nrl.2011.02.005_bib0130","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jns.2009.02.357","article-title":"Rituximab for myasthenia gravis: three case reports and review of the literature","volume":"280","author":"Stieglbauer","year":"2009","journal-title":"J Neurol Sci."},{"key":"10.1016\/j.nrl.2011.02.005_bib0135","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/CND.0b013e31819a8403","article-title":"Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review","volume":"10","author":"Nelson","year":"2009","journal-title":"J Clin Neuromuscul Dis."},{"key":"10.1016\/j.nrl.2011.02.005_bib0140","article-title":"Rituximab in the management of refractory myasthenia gravis","author":"Zebardast","year":"2009","journal-title":"Muscle Nerve."},{"key":"10.1016\/j.nrl.2011.02.005_bib0145","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/mus.21315","article-title":"Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction","volume":"40","author":"Pellkofer","year":"2009","journal-title":"Muscle Nerve."},{"key":"10.1016\/j.nrl.2011.02.005_bib0150","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jbspin.2007.05.011","article-title":"Successful treatment of cardiac involvement in dermatomyositis with rituximab","volume":"75","author":"Touma","year":"2008","journal-title":"Joint Bone Spine."},{"key":"10.1016\/j.nrl.2011.02.005_bib0155","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1002\/art.22856","article-title":"Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients","volume":"56","author":"Cooper","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.nrl.2011.02.005_bib0160","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archderm.143.6.763","article-title":"A pilot trial of rituximab in the treatment of patients with dermatomyositis","volume":"143","author":"Chung","year":"2007","journal-title":"Arch Dermatol."},{"key":"10.1016\/j.nrl.2011.02.005_bib0165","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000114036","article-title":"Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate","volume":"59","author":"Hengstman","year":"2008","journal-title":"Eur Neurol."},{"key":"10.1016\/j.nrl.2011.02.005_bib0170","first-page":"1864","article-title":"Rituximab for refractory polymyositis: an open-label prospective study","volume":"34","author":"Mok","year":"2007","journal-title":"J Rheumatol."},{"key":"10.1016\/j.nrl.2011.02.005_bib0175","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/rheumatology\/kep157","article-title":"Rituximab treatment of the anti-synthetase syndrome: a retrospective case series","volume":"48","author":"Sem","year":"2009","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.nrl.2011.02.005_bib0180","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.nmd.2006.03.002","article-title":"Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP)","volume":"16","author":"Arlet","year":"2006","journal-title":"Neuromuscul Disord."},{"key":"10.1016\/j.nrl.2011.02.005_bib0185","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/rheumatology\/kep027","article-title":"Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion","volume":"48","author":"Whelan","year":"2009","journal-title":"Rheumatology (Oxford)."},{"issue":"2 Suppl 1","key":"10.1016\/j.nrl.2011.02.005_bib0190","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1212\/01.wnl.0000192258.32408.54","article-title":"Pilot trial of etanercept in the treatment of inclusion-body myositis","volume":"66","author":"Barohn","year":"2006","journal-title":"Neurology."},{"key":"10.1016\/j.nrl.2011.02.005_bib0195","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/brain\/awp104","article-title":"Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis","volume":"132","author":"Dalakas","year":"2009","journal-title":"Brain."},{"key":"10.1016\/j.nrl.2011.02.005_bib0200","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/ard.2005.043208","article-title":"Guillain-Barr\u00e9 syndrome in a patient receiving anti-tumour necrosis factor alpha for rheumatoid arthritis: a case report and discussion of literature","volume":"67","author":"Silburn","year":"2008","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.nrl.2011.02.005_bib0205","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/mus.21051","article-title":"Lewis-Sumner syndrome associated with infliximab therapy in rheumatoid arthritis","volume":"38","author":"Hooper","year":"2008","journal-title":"Muscle Nerve."},{"key":"10.1016\/j.nrl.2011.02.005_bib0210","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/mus.20924","article-title":"Tumor necrosis factor-alpha antagonists and neuropathy","volume":"37","author":"St\u00fcbgen","year":"2008","journal-title":"Muscle Nerve."},{"key":"10.1016\/j.nrl.2011.02.005_bib0215","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10067-008-1017-7","article-title":"Miller-Fisher syndrome in a patient with rheumatoid arthritis treated with adalimumab","volume":"28","author":"Kurmann","year":"2009","journal-title":"Clin Rheumatol."}],"container-title":["Neurolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485311001009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485311001009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T05:45:57Z","timestamp":1561355157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213485311001009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0213485311001009"],"URL":"https:\/\/doi.org\/10.1016\/j.nrl.2011.02.005","relation":{},"ISSN":["0213-4853"],"issn-type":[{"value":"0213-4853","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}